VISIPAQUE
Drug
GE HEALTHCARE
Total Payments
$529,983
Transactions
175
Doctors
59
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $175,000 | 3 | 0 |
| 2020 | $3,300 | 3 | 1 |
| 2019 | $93,704 | 30 | 3 |
| 2018 | $213,471 | 81 | 16 |
| 2017 | $44,509 | 58 | 45 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $427,121 | 83 | 80.6% |
| Consulting Fee | $41,758 | 20 | 7.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,371 | 19 | 6.9% |
| Space rental or facility fees (teaching hospital only) | $15,500 | 3 | 2.9% |
| Travel and Lodging | $7,095 | 10 | 1.3% |
| Food and Beverage | $1,140 | 39 | 0.2% |
| Grant | $1,000 | 1 | 0.2% |
Payments by Type
Research
$427,121
83 transactions
General
$102,863
92 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PARALLEL-GROUP, PLACEBO CONTROLLED RANDOMISED STUDY INVESTIGATING THE EFFECT OF INTRAVENOUS ISO-OSMOLAR IODINATED CONTRAST MATERIAL IODIXANOL (VISIPAQUE INJECTION 320MGI/ML) ON RENAL FUNCTION IN ADULTS WITH CHRONIC KIDNEY DISEASE(CKD) STAGE III OR IV WHO HAVE UNDERGONE ENDOVASCULAR ANEURYSM REPAIR (EVAR) | GE HEALTHCARE | $187,883 | 7 |
| VIS2002 Can IodixAnol ReducE the incidence of adverse renal or cardiac events in Chronic Total Occlusion Interventions (CARECTO) | GE HEALTHCARE | $125,000 | 0 |
| PARALLEL-GROUP PLACEBO CONTROLLED RANDOMISED STUDY INVESTIGATING THE EFFECT OF INTRAVENOUS ISO-OSMOLAR IODINATED CONTRAST MATERIAL IODIXANOL (VISIPAQUE INJECTION 320MGI/ML) ON RENAL FUNCTION IN ADULTS WITH CHRONIC KIDNEY DISEASE(CKD) STAGE III OR IV WHO HAVE UNDERGONE ENDOVASCULAR ANEURYSM REPAIR (EVAR) | GE HEALTHCARE | $55,365 | 0 |
| VIS2001 Isoosmolar vs LowOsmolar contrast agents for Optical Coherence Tomography | GE HEALTHCARE | $50,000 | 0 |
| PARALLEL-GROUP PLACEBO CONTROLLED RANDOMISED STUDY INVESTIGATING THE EFFECT OF INTRAVENOUS ISO-OSMOLAR IODINATED CONTRAST MATERIAL IODIXANOL (VISIPAQUE INJECTION 320MGI/ML) ON RENAL FUNCTION IN ADULTS WITH CHRONIC KIDNEY DISEASE(CKD) STAGE III OR IV WHO HAVE UNDERGONE ENDOVASCULAR ANEURYSM REPAIR (EVAR) | GE Healthcare | $8,873 | 0 |
Top Doctors Receiving Payments for VISIPAQUE — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | New York, NY | $487.91 | 1 |
| , MD | Cardiovascular Disease | Sarasota, FL | $29.13 | 1 |
| , M.D, | Cardiovascular Disease | Browns Mills, NJ | $29.13 | 1 |
| , M.D | Cardiovascular Disease | Leawood, KS | $29.13 | 1 |
| , MD | Cardiovascular Disease | Jackson, MS | $29.13 | 1 |
| , M.D | Cardiovascular Disease | Jacksonville, FL | $29.13 | 1 |
| , MD | Cardiovascular Disease | Fairfax, VA | $29.13 | 1 |
| , M.D | Cardiovascular Disease | Nashua, NH | $29.13 | 1 |
| , M.D | Cardiovascular Disease | Simpsonville, SC | $29.13 | 1 |
| , M.D | Interventional Cardiology | Henrico, VA | $29.13 | 1 |
| , MD | Internal Medicine | Atlanta, GA | $29.13 | 1 |
| , M.D | Critical Care Medicine | Fresno, CA | $29.13 | 1 |
| , MD, PHD | Cardiovascular Disease | Detroit, MI | $29.13 | 1 |
| , MD | Specialist | Pittsburgh, PA | $29.13 | 1 |
| , M.D | Cardiovascular Disease | Newton Lower Falls, MA | $29.13 | 1 |
| , M.D | Cardiovascular Disease | Beverly Hills, CA | $29.13 | 1 |
| , MD | Diagnostic Radiology | Miami, FL | $29.13 | 1 |
| , MD | Cardiovascular Disease | Sunrise, FL | $29.13 | 1 |
| , MD | Body Imaging | Nashville, TN | $29.13 | 1 |
| , MD | Cardiovascular Disease | Charleston, WV | $29.13 | 1 |
| , MD | Internal Medicine | Minneapolis, MN | $29.13 | 1 |
| , MD | Cardiovascular Disease | Princeton, NJ | $29.13 | 1 |
| , M.D | Cardiovascular Disease | Quincy, MA | $29.13 | 1 |
| , MD | Cardiovascular Disease | Phoenix, AZ | $29.13 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Philadelphia, PA | $29.13 | 1 |
Ad
Manufacturing Companies
- GE HEALTHCARE $495,523
- GE Healthcare $34,461
Product Information
- Type Drug
- Total Payments $529,983
- Total Doctors 59
- Transactions 175
About VISIPAQUE
VISIPAQUE is a drug associated with $529,983 in payments to 59 healthcare providers, recorded across 175 transactions in the CMS Open Payments database. The primary manufacturer is GE HEALTHCARE.
Payment data is available from 2017 to 2023. In 2023, $175,000 was paid across 3 transactions to 0 doctors.
The most common payment nature for VISIPAQUE is "Unspecified" ($427,121, 80.6% of total).
VISIPAQUE is associated with 5 research studies, including "PARALLEL-GROUP, PLACEBO CONTROLLED RANDOMISED STUDY INVESTIGATING THE EFFECT OF INTRAVENOUS ISO-OSMOLAR IODINATED CONTRAST MATERIAL IODIXANOL (VISIPAQUE INJECTION 320MGI/ML) ON RENAL FUNCTION IN ADULTS WITH CHRONIC KIDNEY DISEASE(CKD) STAGE III OR IV WHO HAVE UNDERGONE ENDOVASCULAR ANEURYSM REPAIR (EVAR)" ($187,883).